DS
LABP

David Shaw’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

David Shaw’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,699
Closed -$25K – 5959
2022
Q1 		$25K Buy
+1,699
New +$43.2K ﹤0.01% 5303

Other funds holding LABP

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's LABP Position: Q2 2022 in Review

David Shaw sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2022, closing a stake of 1,699 shares — an estimated $25K sold.

David Shaw first reported a position in LABP in Q1 2022 and held it in 1 quarter. The position peaked at $25K in Q1 2022. 34 funds tracked by Wall St. Rank hold LABP as of Q2 2022.

  • David Shaw reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 1,699 Landos Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $25K.
  • David Shaw first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • David Shaw's Landos Biopharma, Inc. Common Stock position peaked at $25K in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.